/ /

  • linkedin
  • Increase Font
  • Sharebar

    Incorporating meibomian gland imaging

    Dry eye disease (DED) is nothing new, but how eyecare practitioners diagnose and monitor DED has evolved due to new technology. In-office laboratory tests such as TearLab Osmolarity System and RPS InflammaDry and equipment such as Oculus Keratograph 5M or TearScience LipiView give us better information to manage our dry eye patients. 

    Optometry and dry eye

    Establishing a dry eye clinic in your practice does not require a large financial investment, nor does it require a marketing campaign for potential dry eye patients. Nearly half of all U.S. adults (about 48 percent) experience one or more dry eye symptoms regularly, according to an Allergan survey,1 so many of your current patients will benefit from your ability to properly diagnose and treat their DED.

    Optometrists are perfectly positioned to be the primary eyecare provider for those millions of dry eye sufferers because a common complaint for these patients is blurry vision. Today’s digital age provides many benefits such as computers, smartphones and tablets as well as the disadvantage of increasing dry eye symptoms caused by the reduced blink rate associated with up-close tasks.

    If you ask your patients the right questions, you will elicit the complaints caused by tear film deficiency and meibomian gland dysfunction (MGD). Performing the right tests enables you to diagnose and treat the ocular surface disease, providing comfortable and clear vision for your patients suffering from DED.2

    Eric Botts, OD
    Dr. Botts owns InnovativEYES clinics located in Walmart Vision Centers in Macomb and Galesburg, IL, and West Burlington, IA. He assists ...

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Optometry Times A/V